This will ensure that we pursue therapy, rather than mere drug development [38], to solve the challenges of tumor heterogeneity, e.g., treating both AR+, PSA-producing, differentiated progeny cells and AR-, non-PSA producing, stem-like progenitor cells. The gene discussed is AR; the disease is neoplasm.